CHICAGO, Sept. 8, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Diageo Plc. (NYSE: DEO), Fortune Brands Inc. (NYSE: FO), Anheuser-Busch InBev (NYSE: BUD), Molson Coors Brewing Company's (NYSE: TAP) and Biogen Idec (Nasdaq: BIIB).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday's Analyst Blog:
Diageo Recycles Byproduct for Energy
Global spirit giant Diageo Plc. (NYSE: DEO) has decided to invest $9.6 million for building a bioenergy plant that will recycle draff and reuse it for generating energy. The multinational has decided to set up the plant near Elgin, Scotland in Glenlossie distillery complex at Speyside.
Draff is a byproduct of the grain that is used for making whisky. After distilling 12 million liters of whiskey the bioenergy plant will have almost 30,000 tones of draff at its disposal. This large amount of draff will be supplied by 17 malt whisky distilleries – situated around the biomass plant in Speyside.
Energy produced will help power operations on site, including Glenlossie and Mannochmore distilleries and the onsite dark grains plant, which makes animal feed. The bioenergy plant will make an important contribution to Diageo's global environmental targets by reducing annual carbon dioxide emissions by approximately 6,000 tones.
Diageo is set to expand its business in Speyside, Scotland. Recently Diageo was part of an industry consortium that constructed a biomass combined heat and power plant, which was hailed as a major breakthrough for Scotland's renowned alcohol industry.
The spirit maker is also investing for increasing capacity at the Glen Ord distillery near Inverness and at its Caol Ila distillery in Islay. It also announced a huge investment for expanding its malt whisky distillation capacity in Speyside over the next two-to-three years. The expansion in distillation will allow Diageo's Speyside distilleries to produce an extra 10 million liters of alcohol per year.
Diageo Plc.'s fiscal 2011 net income from continuing operations grew 16.1% to £2.02 billion ($3.3 billion) from £1.74 billion in the year-ago period. Earnings per share came in at 76 pence ($1.24 per ADR), compared to £0.65 per share in the year-ago quarter.
The recent economic downturn has left Diageo shaken. Besides, the stiff competition from Pernod Ricard and Fortune Brands Inc. (NYSE: FO) in the spirits business and Anheuser-Busch InBev (NYSE: BUD) and Molson Coors Brewing Company's (NYSE: TAP) beer business undermines Diageo's value in the eyes of the investors.
Diageo holds a Zacks #2 Rank, which translates into a short-term Buy rating.
Biogen to Fully Acquire Dompe JV
Biogen Idec (Nasdaq: BIIB) recently announced its intention to acquire 100% of Dompé's shares in its joint ventures (JVs) in Italy and Switzerland. Biogen and Dompé had entered into a joint venture in 1997. While the joint venture was initially focused on the commercialization of Avonex, the collaboration was later expanded to include commercial, distribution and service rights for Tysabri.
Once Biogen gains full control of the joint ventures, it will have a direct commercial presence in 29 countries. The company said that the new affiliate offices will be named Biogen Idec Italia and Biogen Idec Switzerland. Financial terms of the agreement were not disclosed.
This move will allow both Biogen and Dompé to focus on their core business areas. Over the past few months, Biogen has been working on streamlining its operations.
In November 2010, the company had announced its intention to streamline its operations and increase efficiencies through the implementation of a restructuring program. The company's restructuring program includes initiatives like streamlining of operations, shutting down of facilities, and workforce reduction.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
SOURCE Zacks Investment Research, Inc.